We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+8.23%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$3.74B
AUM Growth
-$74.6M
Cap. Flow
-$183M
Cap. Flow %
-4.9%
Top 10 Hldgs %
49.32%
Holding
151
New
26
Increased
20
Reduced
26
Closed
34

Top Buys

Rank Stock Value
1
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$76.8M
2
ATNX
Athenex, Inc. Common Stock
ATNX
+$47.1M
3
VRAY
ViewRay, Inc.
VRAY
+$35.6M
4
ARNA
Arena Pharmaceuticals Inc
ARNA
+$21.3M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$20.4M

Top Sells

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$65.3M
2
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$64.5M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$57.5M
4
HUM icon
Humana
HUM
+$36.8M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$35.2M

Sector Composition

Rank Sector Weight
1 Healthcare 90.69%
2 Financials 0.17%
3 Consumer Discretionary 0.05%
4 Industrials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NBIX icon
1
Neurocrine Biosciences
NBIX
$18.3B
$587M 15.71%
4,777,254
+62,004
+1% +$7.03M
FOLD
2
DELISTED
Amicus Therapeutics
FOLD
$250M 6.69%
20,694,424
+670,000
+3% +$9.37M
GBT
3
DELISTED
Global Blood Therapeutics, Inc.
GBT
$196M 5.23%
5,148,910
+320,000
+7% +$14.2M
ZGNX
4
DELISTED
Zogenix, Inc.
ZGNX
$189M 5.05%
3,807,632
-162,725
-4% -$8.28M
ALNY icon
5
Alnylam Pharmaceuticals
ALNY
$38.6B
$105M 2.8%
1,197,994
-648,917
-35% -$65.3M
XLRN
6
DELISTED
Acceleron Pharma
XLRN
$87.5M 2.34%
1,528,205
– –
LJPC
7
DELISTED
La Jolla Pharmaceutical Company
LJPC
$86.8M 2.32%
4,313,611
– –
IOVA icon
8
Iovance Biotherapeutics
IOVA
$2.04B
$82M 2.19%
7,290,199
+1,437,997
+25% +$20.4M
ASND icon
9
Ascendis Pharma A/S
ASND
$16.8B
$76M 2.03%
1,072,647
– –
CRNX icon
10
Crinetics Pharmaceuticals
CRNX
$8.88B
$74.1M 1.98%
+2,587,953
New +$76.8M
BPMC
11
DELISTED
Blueprint Medicines
BPMC
$73.5M 1.96%
941,147
-20,000
-2% -$1.39M
MYOK
12
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$71M 1.9%
1,089,169
– –
DBVT
13
DBV Technologies
DBVT
$803M
$67.6M 1.81%
301,000
+90,180
+43% +$18.3M
QTNT
14
DELISTED
Quotient Limited Ordinary Shares
QTNT
$66.4M 1.77%
219,726
+57,650
+36% +$17.3M
DOVA
15
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
$65.5M 1.75%
3,125,851
– –
MGTX icon
16
MeiraGTx Holdings
MGTX
$1.08B
$64M 1.71%
4,703,398
– –
ARNA
17
DELISTED
Arena Pharmaceuticals Inc
ARNA
$62.9M 1.68%
1,366,978
+525,000
+62% +$21.3M
MMSI icon
18
Merit Medical Systems
MMSI
$4.74B
$61.1M 1.63%
994,198
-87,815
-8% -$5.04M
TVTX icon
19
Travere Therapeutics
TVTX
$5.14B
$60.5M 1.62%
3,212,871
– –
CORI
20
DELISTED
Corium International, Inc.
CORI
$60.5M 1.62%
6,357,133
– –
ALBO
21
DELISTED
Albireo Pharma Inc
ALBO
$56.2M 1.5%
1,704,330
– –
VRCA icon
22
Verrica Pharmaceuticals
VRCA
$92.9M
$55.4M 1.48%
341,041
– –
CTMX icon
23
CytomX Therapeutics
CTMX
$694M
$49.2M 1.32%
2,661,715
+740,000
+39% +$16.9M
ATNX
24
DELISTED
Athenex, Inc. Common Stock
ATNX
$44.6M 1.19%
143,476
+133,976
+1,410% +$47.1M
KDMN
25
DELISTED
Kadmon Holdings, Inc.
KDMN
$44M 1.18%
13,165,746
– –
1
2 3 4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q3 2018 Portfolio in Review

As of Q3 2018, Perceptive Advisors held 151 positions worth $3.74B, down 2% from $3.81B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Perceptive Advisors withdrew a net $183M in Q3 2018, closing 34 positions and reducing 26 holdings. Its most notable exit was Alexion Pharmaceuticals, an estimated $57.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 93% a quarter earlier, followed by Financials and Consumer Discretionary.

Against the trend, Perceptive Advisors opened a new position in Crinetics Pharmaceuticals worth $74.1M.

  • Perceptive Advisors's largest Q3 2018 buy was Crinetics Pharmaceuticals: 2,587,953 shares worth $74.1M.
  • Perceptive Advisors added most to Athenex, Inc. Common Stock in Q3 2018, an estimated $47.1M increase.
  • Perceptive Advisors's biggest Q3 2018 reduction was Alnylam Pharmaceuticals, cutting an estimated $65.3M.
  • Perceptive Advisors fully exited Alexion Pharmaceuticals in Q3 2018, selling an estimated $57.5M.
  • Perceptive Advisors's ten largest holdings make up 49% of its $3.74B portfolio in Q3 2018.
  • Perceptive Advisors opened 26 new positions and closed 34 in Q3 2018.
  • Perceptive Advisors's portfolio value fell 2% quarter-over-quarter to $3.74B.

Based on Perceptive Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.